Skip to main content

Table 1 Patient baseline demographic and clinical characteristics (N = 102)

From: Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Patient characteristics N (%)
Age
 Median age, years (range) 52.5 (18–78)
 < 65 87 (85.3)
 ≥ 65 15 (14.7)
Gender
 Male 70 (68.6)
 Female 32 (31.4)
ECOG PS
 0 19 (18.6)
 1 83 (81.4)
Prior lines of systemic therapy
 1 42 (41.2)
 2 34 (33.3)
 3 or above 26 (25.5)
Stage of disease#
 I–II 17 (16.7)
 III–IV 84 (82.4)
Pathological subtype$
 PTCL-NOS 41 (40.2)
 ENKTL 23 (22.5)
 ALCL ALK- 12 (11.8)
 ALCL ALK+ 7 (6.9)
 Other subtypes* 19(18.6)
Prior therapies
 Multi-agent regimen
  For ENKTL
   Asparaginase-based chemotherapy 21 (91.3)
  For other subtypes of PTCL
   Anthracycline-containing chemotherapy 77 (97.5)
Single-agent regimen
 Chidamide 24 (23.5)
 Gemcitabine 55 (53.9)
 Methotrexate 10 (9.8)
 Bortezomib 1 (1.0)
Radiotherapy 32 (31.4)
Autologous stem-cell transplantation 7 (6.9)
  1. ENKTL, extranodal natural killer/T cell lymphoma, nasal type; ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ECOG, Eastern Cooperative Oncology Group; PS, performance status; NOS, not otherwise specified; PTCL, peripheral T cell lymphoma
  2. #Stage information of one case was not available
  3. $PTCL was pathologically diagnosed by study site pathologist for study enrolment
  4. *Other subtypes included: 11 cases of unclassifiable PTCL, 3 cases of type II enteropathy-associated T cell lymphoma (EATL, type II), 3 cases of mycosis fungoides (MF), 1 case of skin γ σ cutaneous T cell lymphomas (γ σ CTCL), and 1 case of primary cutaneous CD4 positive T cell lymphoma (CD4 + PCTCL)
  5. The proportion (%) was defined as the number of patients receiving asparaginase-based chemotherapy divided by the number of those diagnosed with ENKTL
  6. The proportion (%) was defined as the number of patients receiving anthracycline-containing chemotherapy divided by the number of those diagnosed with other subtypes of PTCL except for ENKTL